Why tech transfer may be critical to beating COVID-19
Contenido multimedia no disponible por derechos de autor o por acceso restringido. Contacte con la institución para más información.
| Tag | 1 | 2 | Valor |
|---|---|---|---|
| LDR | 00000cam a22000004b 4500 | ||
| 001 | MAP20200026976 | ||
| 003 | MAP | ||
| 005 | 20220912143618.0 | ||
| 008 | 180511e20200701usa|||| ||| ||eng d | ||
| 040 | $aMAP$bspa$dMAP | ||
| 084 | $a922.111 | ||
| 100 | 1 | $0MAPA20200017950$aO'Sullivan, Cormac | |
| 245 | 1 | 4 | $aWhy tech transfer may be critical to beating COVID-19$cCormac O'Sullivan, Paul Rutten, Caspar Schatz |
| 260 | $aNew York$bMcKinsey & Company$c2020 | ||
| 300 | $a8 p. | ||
| 490 | 0 | $aPharmaceuticals & Medical Products Practice | |
| 520 | $aVaccines are considered to be our best chance for beating COVID-19, and many governments are counting on them to enable economic recovery. But to innoculate people worldwide as soon as vaccines are proven will require the pharmaceutical industry to ramp up quickly to unprecedented volumes of supply. The available global production capacity will be critical to that capability. And technology transfermoving the knowledge about and the ability to produce a vaccine from development to manufacturingwill determine how fast it happens. But tech transfer is as much a craft as a science. And it hasn't usually been on the critical path to production, so it comprises an underappreciated set of capabilities. To ensure adequate and timely supplies of COVID-19 vaccines and treatments, global institutions and pharma companies must collaborate to make tech transfer an industrialized, at-scale processbefore we need it. | ||
| 650 | 4 | $0MAPA20200005599$aCOVID-19 | |
| 650 | 4 | $0MAPA20200005391$aCoronavirus | |
| 650 | 4 | $0MAPA20080552022$aPandemias | |
| 650 | 4 | $0MAPA20080556884$aVacunación | |
| 650 | 4 | $0MAPA20080605674$aDesarrollo tecnológico | |
| 650 | 4 | $0MAPA20080606633$aIndustria farmacéutica | |
| 650 | 4 | $0MAPA20080606787$aInnovación empresarial | |
| 650 | 4 | $0MAPA20080619749$aLaboratorios farmacéuticos | |
| 700 | 1 | $0MAPA20200017967$aRutten, Paul | |
| 700 | 1 | $0MAPA20200017981$aSchatz, Caspar | |
| 710 | 2 | $0MAPA20080442569$aMcKinsey & Company | |
| 830 | 0 | $0MAPA20200017998$aPharmaceuticals & Medical Products Practice |